CLLS | Cellectis SA
Next ER: August 7, 2023
About the Company
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris and New York City.
NASDAQ - Nasdaq Stock Market
More profiles and info about the company
This company doesn't provide a dividend.
Talk about Cellectis SA below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Very few careers can offer you the freedom, flexibility, and income that day trading does. As a day trader, you can live and work anywhere in the world. You can decide when to work and when not to work. You only answer to yourself. That is the life of the successful day trader. Many people aspire to it, but very few succeed.
A Beginner's Guide to Trading Tools and Tactics, Money Management, Discipline and Trading Psychology